Quality of Life in Cutaneous Lymphoma Patients Using the Skindex29

Status Recruiting

Clinical Trial Summary

This study assesses the quality of life in patients with cutaneous lymphoma diagnosis as it relates to their personal, clinical, and therapeutic information using the Skindex29 questionnaire and also assesses patients' understanding of their diagnosis and need for resources related to their care. Cutaneous lymphomas are a rare type of blood cancers (non-Hodgkin lymphoma) that present in the skin. The information gained from this study, may help researchers improve quality of life in cutaneous lymphoma patients.

Clinical Trial Description

PRIMARY OBJECTIVES: I. To prospectively assess quality of life (QoL) in adult patients with cutaneous lymphoma (CL) via use of a validated questionnaire (Skindex-29) and identify the psychosocial needs of our patient population. II. To prospectively evaluate the burden of pruritus in patients with CL via use of 10-point pruritus scale and compare to QoL. III. To evaluate QoL for any correlation with demographic and clinical information, specifically, age, gender, race/ethnicity, type of CL, stage of mycosis fungoides (MF)/Sezary syndrome (SS), treatment regimen, and social work involvement. IV. To track changes in QoL and burden of pruritus as they relate to therapeutic strategies used to manage disease, including social work involvement. V. To prospectively assess patients' knowledge and understanding of their cancer diagnosis, prognosis, and overall survival; and to track changes in their knowledge and understanding, and assess for any correlation to QoL. VI. To prospectively evaluate our patients' need for resources, and our ability to meet those needs; and to assess for any correlation to demographic or clinical category, or QoL. OUTLINE: Patients complete quality of life questionnaires over 10-20 minutes about symptoms, emotions, and functioning related to diagnosis of cutaneous lymphoma. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04670874
Study type	Observational
Source	City of Hope Medical Center
Contact
Status	Recruiting
Phase
Start date	August 17, 2023
Completion date	January 24, 2034

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT04520529` - Identification of Prognostic Factors and New Therapeutic Targets in Cutaneous Lymphomas	N/A
Completed	`NCT01902225` - Phase I Dose-finding and Preliminary Efficacy Study of the Istodax® in Combination With Doxil® for the Treatment of Adults With Relapsed or Refractory Cutaneous T-cell Lymphoma	Phase 1
Completed	`NCT00400556` - ATRA Plus G-CSF for Mobilization of Hematopoietic Stem and Progenitor Cells	Phase 1
Active, not recruiting	`NCT01396070` - Pilot Study of Brentuximab Vedotin (SGN-35) in Patients With MF With Variable CD30 Expression Level	N/A
Terminated	`NCT01556828` - Analysis of Cutaneous and Hematologic Disorders by High-Throughput Nucleic Acid Sequencing	N/A
Terminated	`NCT01187446` - Low-dose (12 Gy) TSEBT+Vorinostat Versus Low-dose TSEBT Monotherapy in Mycosis Fungoides	Phase 1/Phase 2
Recruiting	`NCT03602157` - Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL	Phase 1
Completed	`NCT03458117` - T-VEC in Non-melanoma Skin Cancer	Phase 1